plerixafor has been researched along with Leukocytopenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aprikyan, A; Bolyard, AA; Dale, DC; Hsu, FJ; Kelley, ML; Makaryan, V; Westrup, EC; Wood, B | 1 |
| Calandra, G; Gandhi, PJ; Jacobsen, ED; Micallef, IN; Shaughnessy, P; Uberti, J; van Rhee, F | 1 |
1 trial(s) available for plerixafor and Leukocytopenia
| Article | Year |
|---|---|
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Bone Marrow Diseases; Cyclams; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Precursor Cells; Heterocyclic Compounds; Humans; Immunologic Deficiency Syndromes; Leukopenia; Male; Middle Aged; Primary Immunodeficiency Diseases; Receptors, CXCR4; Warts | 2011 |
1 other study(ies) available for plerixafor and Leukocytopenia
| Article | Year |
|---|---|
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.
Topics: Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukocyte Count; Leukopenia; Lymphoma, Non-Hodgkin; Multiple Myeloma; Platelet Count; Retrospective Studies; Thrombocytopenia | 2013 |